Author

Paul Porter

Baylor College of Medicine

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

Alex J. SmithiD· 1 shared C. Zhang· 1 shared Charles M. PerouiD· 1 shared Constanze V. OehleriD· 1 shared Diego A. PedrozaiD· 1 shared Fengshuo LiuiD· 1 shared Hilda L. ChaniD· 1 shared Jeffrey M. RoseniD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alex J. SmithORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Anti-CSF-1R therapy with combined immuno- chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched Triple Negative Breast Cancers

Diego A. Pedroza, Xueying Yuan, Fengshuo Liu, Hilda L. Chan, C. Zhang, William Bowie, Alex J. Smith, Sebastian J. Calderon, Nadia Lieu, Weiguo Wu, Paul Porter, Poonam Sarkar, Na Zhao, Constanze V. Oehler, Ondrej Peller, , Jeffrey M. Rosen

The paper shows that combining anti-CSF-1R therapy with chemotherapy and anti-PD-1 improves immune response in metastatic TNBC by reducing macrophages and increasing T/B cell infiltration.

Nature Communications · Jan 3, 2026Peer-reviewedCancer Biology